



Sobrero Pharma AB Strengthens Its Board with Key Appointments as the Company Accelerates Toward 2026 Milestones

Gothenburg, Sweden – January 22, 2026

Sobrero Pharma AB today announced the appointment of **James Gamgort** and **Lars Hallmayer** to its Board of Directors, further strengthening the company's leadership as it enters a highly active and value-creating phase of development.

The appointments come at a pivotal time for Sobrero as the company prepares for several important milestones in 2026. The new appointments mark a crucial moment for Sobrero, bringing valuable expertise to the board as the company gears up for key milestones in 2026.

James Gamgort, is currently Chief Commercial Officer and Managing Partner Encompass Communications and Learning, Inc., brings extensive international experience in pharmaceutical commercialization, business development, and strategic partnerships, with a particularly strong track record in the U.S. market. **Lars Hallmayer**, Managing Director at Welding Group, contributes with strong industrial and technical expertise in pharmaceutical development, formulation, and the efficient execution of complex development programs.

“With these appointments, Sobrero now has a Board with a level of international, commercial, and industrial experience that is highly competitive by global standards and well aligned with the company’s next phase of development,” said Jan-Fredrik Backman, Chairman of the Board.

“This is a deliberate step as we move from preparation into execution, where regulatory engagement, formulation development, and strategic positioning become increasingly critical.”

Ann-Charlotte Rosendahl, CEO of Sobrero Pharma AB, added:

“We are entering an exciting and demanding phase for the company. Expanding the Board with this level of international and industrial expertise strengthens our ability to execute with focus, speed, and quality. I look forward to working closely with James and Lars as we continue to build long-term value in Sobrero.”

With a reinforced Board and a clear development roadmap, Sobrero is well-positioned to advance its program and maintain strong momentum throughout 2026.

About Sobrero Pharma AB

Sobrero Pharma AB is a privately held clinical-stage pharmaceutical company focused on developing innovative treatments for patients with Alcohol Use Disorder (AUD). The company's mission is to address significant unmet medical needs through differentiated, science-driven therapeutic solutions.

For more information, please visit: www.sobrero.com

About AUD

Alcohol Use Disorder (AUD) affects an estimated 280 million people worldwide, yet fewer than 3% receive pharmacological treatment. Despite its severe consequences to patients, their families and society, the condition remains one of the most under-treated areas in medicine, highlighting both a substantial unmet medical need and a significant opportunity for new therapeutic solutions.